Today, the best treatments of patients with NSCLC with activating EGFR mutations are third-generation EGFR TKI rosimertinib and a combination of first-generation EGFR TKI and chemotherapy [208]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.